Author

GIORGIA IADANZA

IL-6 INHIBITOR AS PALLIATIVE TREATMENT FOR A 63 YEARS-OLD MALE PATIENT SUFFERING STAUFFER’S SYNDROME-RELATED PARANEOPLASTIC CHOLESTASIS
IL-6 INHIBITOR AS PALLIATIVE TREATMENT FOR A 63 YEARS-OLD MALE PATIENT SUFFERING STAUFFER’S SYNDROME-RELATED PARANEOPLASTIC CHOLESTASIS

GIORGIA IADANZA  et al.

EFFECTS OF GUT MICROBIOTA ON ANTITUMOR ACTIVITY IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CETUXIMAB PLUS AVELUMAB
EFFECTS OF GUT MICROBIOTA ON ANTITUMOR ACTIVITY IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CETUXIMAB PLUS AVELUMAB

GIORGIA IADANZA  et al.

SYSTEMIC OXIDATIVE STRESS-UNBALANCE IN PBC PATIENTS: A PRELIMINARY OBSERVATION ON CORRELATION WITH LIVER DISEASE PROGRESSION
SYSTEMIC OXIDATIVE STRESS-UNBALANCE IN PBC PATIENTS: A PRELIMINARY OBSERVATION ON CORRELATION WITH LIVER DISEASE PROGRESSION

GIORGIA IADANZA  et al.

ADVANCED FIBROSIS AND CARDIOVASCULAR RISK PREDICTION IN MAFLD: THE ALPHA-GLUTATHIONE-S-TRANSFERASE (ALPHAGST) AND THE “METABOLIC ABNORMALITIES-AST/PLATELET RATIO- INFLAMMATION-ALPHAGST LEVELS” (MARINA) INDEX AS A NOVEL PREDICTIVE BIOMARKER AND COMPOSITE T
ADVANCED FIBROSIS AND CARDIOVASCULAR RISK PREDICTION IN MAFLD: THE ALPHA-GLUTATHIONE-S-TRANSFERASE (ALPHAGST) AND THE “METABOLIC ABNORMALITIES-AST/PLATELET RATIO- INFLAMMATION-ALPHAGST LEVELS” (MARINA) INDEX AS A NOVEL PREDICTIVE BIOMARKER AND COMPOSITE T

GIORGIA IADANZA  et al.

HEPATOBILIARY DISORDERS IN INFLAMMATORY BOWEL DISEASE: WHAT COULD BE THE OPTIMAL MANAGEMENT WHEN PRIMARY BILIARY CHOLANGITIS PRECEDES THE ONSET OF CROHN ILEITIS? A SIXTY-SIX YEARS OLD FEMALE PATIENT CASE REPORT
HEPATOBILIARY DISORDERS IN INFLAMMATORY BOWEL DISEASE: WHAT COULD BE THE OPTIMAL MANAGEMENT WHEN PRIMARY BILIARY CHOLANGITIS PRECEDES THE ONSET OF CROHN ILEITIS? A SIXTY-SIX YEARS OLD FEMALE PATIENT CASE REPORT

GIORGIA IADANZA  et al.

HEPATOCELLULAR CARCINOMA (HCC) OCCURRENCE IN A LYSOSOMAL ACID LIPASE DEFICIENCY (LALD)-AFFECTED 49-YEARS OLD NON-CIRRHOTIC MALE: HOW TO MANAGE THE MALIGNANCY IN THIS RARE LIVER-DISEASE CONTEXT?
HEPATOCELLULAR CARCINOMA (HCC) OCCURRENCE IN A LYSOSOMAL ACID LIPASE DEFICIENCY (LALD)-AFFECTED 49-YEARS OLD NON-CIRRHOTIC MALE: HOW TO MANAGE THE MALIGNANCY IN THIS RARE LIVER-DISEASE CONTEXT?

GIORGIA IADANZA  et al.

THE INFLUENCE OF SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) LIFESTYLE CHANGES ON METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE (MAFLD) EVOLUTION: A MATTER OF BODY COMPOSITION
THE INFLUENCE OF SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) LIFESTYLE CHANGES ON METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE (MAFLD) EVOLUTION: A MATTER OF BODY COMPOSITION

GIORGIA IADANZA  et al.

Item 1 - 7 / 7
1